Surgery alone can cure only 15-20% of patients with localized high grade osteosarcoma.

Sarcomata of the osteogenic Series Mac Kenna et coll...J.B.J.S. 1966,48-A,1;1-26
Chemotherapy alone can never cure an osteosarcoma.

- N. Jaffe tried intensive, prolonged chemotherapy in patients with spine inoperable OS. After some stabilization all tumor recurred.

- Comprehensive treatment remains the gold standard but the optimal schedule of chemotherapy and surgery remains controversial.

- The aim of this review is to propose an optimal schedule of treatment based on Rosen’s rationale and our own experience.
Jaffe demonstrated the correlation dose intensity of MTX/Response of OS.

- High Dose Methotrexate (HDMTX) administered every 3 weeks obtain 30\% response.
- but 87\% when administered every week at higher dosage.

Récent advances in the chemotherapy of metastatic osteosarcoma  
"Weekly HDMTX and citrovum factor in osteogenic sarcoma"  
Cancer 1972,30: 1627  
Cancer 1977, 39 : 45
Strategy of Rosen T5 protocol

- Rosen thought that the follow up of the tumor during chemotherapy could permit to realize an antimitogramme in vivo
- He gave preoperative chemotherapy to determine the optimal dose for a particular patient.

Preoperative chemotherapy permits to find “the optimal dosage” for individual patient.

TABLE 4. Rationale for Preoperative Chemotherapy

1. Early treatment of systemic micrometastases
2. Determine optimal dosage for individual patient by observing regression of primary tumor
2a. Determine dosage for future adjuvant chemotherapy
3. Time to plan definitive local therapy for primary tumor
4. Preservation of limb function
   The addition of chemotherapy as another modality for the treatment of the primary tumor may permit the preservation of more normal tissue at the time of definitive local therapy

The rationale for preoperative chemotherapy is primarily to achieve a higher cure rate in osteogenic sarcoma through the use of early systemic treatment with reduced local recurrence.
30 years ago G Rosen underlined that preoperative chemotherapy is an investigative method, Not a recipe.

Chemotherapy for Osteogenic Sarcoma: An Investigative Method, Not a Recipe

Gerald Rosen* and Anita Nirenberg

The controversy over the role of chemotherapy for the treatment of osteogenic sarcoma arises because osteogenic sarcoma has been in the past and always will be a difficult and resistant tumor to treat with chemotherapy. In the majority of instances, the various protocols employed have been directed toward extending survival by any means possible, using high-dose methotrexate (HDMTX) as an example. HDMTX has been used to treat patients with evaluable primary tumors. Experience in the direct observation of patients with evaluable disease who received this treatment has allowed us to determine the optimal dose of high-dose methotrexate for each patient. In addition, extensive pharmacokinetic studies

1Received Mar 22, 1982; accepted Apr 8, 1982.
2Departments of Pediatrics (G. Rosen and A. Nirenberg) and Medicine (G. Rosen), Memorial Sloan-Kettering Cancer Center, New York, NY.

Cancer Treatment Reports Vol. 66, No. 9, September 1982

Allowed us to determine the optimal dose of HDMTX for each patient
T5 protocol strategy was successful

- The T5 protocol based on pre and post operative HDMTX (8 G/m²) and Doxorubicin obtained 75% disease free survival.
- And permit to observe that children needed usually more MTX (12 G/m² vs 8 G/m²)

Strategy of T7

- In the T7 the first dose of MTX of children under 12 years was increased, while adults received 8 g/m².
- Postoperative chemotherapy was identique for good and bad responders defined on histologic examination of the primary resected after preop chemotherapy.
- Bad responders had a lower EFS than good responders confirming the rosen’s hypothesis that primary was representative of micrometastases.
Strategy of T10

• In the T10 protocol the postoperative chemotherapy was different for good and bad responders.
• Postoperative chemotherapy for good responders used the same drugs (HDMTX, Doxo, BCD) up to 20 curses of MTX.
• Bad responders continued on HDMTX but received a chemotherapy reinforced by CDDP instead of BCD.
• This post operative chemotherapy rescued the bad responders.
T10 protocols were successful.


DFS = 82%
But after he published his results, the medical community retains the recipe and forgot the underlying philosophy.

In all multicentric trials a fixed dose of MTX was administered.

And published results were all under Rosen T7 and T10.
Results of SFOP " T10 "1979-1986

ROSEN T7+T10

N = 105. D.F.S. = 53%

T10 de la Société Française d’Oncologie Pédiatrique

Mean value of EFS of 610 patients include in EIO trials is 46%
For more than 25 years a lot of multicentric trials on treatment of OS have been made.

- Global results are disappointing both on scientific and medical points of view:
  - Very few hypotheses have been definitively confirmed and very new concepts emerged.
  - Efs of patients did not increased significantly.
Very few scientific data have been definitively confirmed

- Discordant data have been published and do not confirm the major hypotheses of Rosen:
  - Does’ Preoperative chemotherapy improve DFS?
  - Is response predictive of DFS?
  - Does HDMTX improve DFS?
  - Which the optimal dose of HDMTX?
  - Can postop chemotherapy rescue bad responders?
Despite the quality of colleagues, statisticians and methods, multicentric trials globally failed.

- Multicentric trials study the « mean patient » with the « mean osteosarcoma » supposing that all patients and all osteosarcoma are comparable.
- They ignore our metabolic differences.
- But we are all unique, all different.
- And osteosarcoma are all unique, all different.
Every human being is unique at birth.
Every human being is unique at birth.
We are all different: 3 main races

- And so many others..
When we grow our experiences (food, illness, medications, environmental status) are unique and increase our differences.

Strategy of treatment of osteosarcoma  
XII national congress of tchek orthopaedics May 18 2008 Praha
We are all different, all unique:
Different weights

540kg
33Kg
32kg
We are all different, all unique: Different sizes

These differences are not well balanced by dosage in gr/sqm
We are all unique, all different. And also our pharmacokinetiks of anticancer drugs.

Interindividual variability of Serum peak of MTX after an 6 hours infusion of 12 grs/ M²
Tailoring the dose according individual PK

• permits to overcome the inter individual variability for optimal therapeutic use.

• If you infuse 12gr/sqm of MTX in 6 hours the peak of methotrexatemia can reach 2500 µmol /L or 350µmol/L resulting in increased risk of toxicity for some patients or ineffectiveness of treatment for others.
But Osteosarcoma are all different, all unique.

• Many histologic subtypes:
  – commun type
  – anaplastic
  – chondroblastic
  – telangectasic
  – fibroblastic...

• Many radiologic subtypes:

• Many differents of cellular drug resistance. The presumed intrinsic MTX resistance has been ascribed to an impaired MTX polyglutamylation associated. In addition, MTX uptake may be defective as observed whereas also high levels of (altered) DHFR have been reported.

• Many differents of oncogenes expression
such situation is comparable to treatment of severe bacteriemia.

- Bacteriologists use pharmacokinetics to adapt dose of antibiotics
- and antibiogram to evaluate the efficient serum concentration.
Which drug?

- Only two agents effective against osteosarcoma have a large therapeutic index permitting significant increase of dose: MTX and Ifosfamide.

- These two drugs demonstrated a dose/effect correlation on osteosarcoma.
Why do we prefer HDMTX?

- MTX offers many advantages: It represents the only drug whose total dose and dose intensity are statistically correlated with 5 year disease free survival of patients
  - it can be infused with a weekly interval,
  - the pharmacokinetics can be easily studied,
  - the toxicity can be rescued by folinic acid,
  - and aplasia is usually not a problem when MTX is administrated in monotherapy.
- For these reasons we use only MTX in preop CHT.
We have observed that mean methotrexatemia during preoperative phase is correlated with response.

Scandinavian confirmed the correlation of methotrexatemia and histologic response.

Pronostic value of H6 Methotrexatemia

PROTOCOLE RIZZOLI 2

% EFS vs Months from biopsy

- > 700 µMol/ L
- < 700 µ mol/ L

P = 0.001

GRAF N. Pronostic value of H4 methotrexatemia

% EFS

Years from biopsy

Graf N. and all. Einfluss der Methotrextapharmakokinetik und... Klin. Padiatr. 202; 1990: 340-346
With MTX, More you give ,more you obtain
Correlation DFS/ Dose intensity of MTX

But no gold standard for dose of MTX!

- **Pharmacokinetics of patients are individual.**
- Resulting for a fixed dose, in increased risk of toxicity for some patients and ineffectiveness of treatment for many others.
We tried to apply Rosen’s rationale

- As soon after biopsy we start with HDMTX (8 to 15 G/Sqm according to age) with complete PK study.
- On D7 the second curse is administered with a tailored dose to obtain:
  - a clinical response of the primary (decreasing of local hyperthermia and vascularisation).
  - And a serum peak of 1000μmole/L

Escalating doses of MTX

0 1 2 3 4 Weeks

Biopsy Resection
During preoperative chemotherapy the surgeon must evaluate the tumor every week

- we increase the dose
- If the serum peak is too low
- less than 1000μmol/l if infusion of 6 hours
- Rosen propose 1450μmol/l for an infusion of 4 hours
- if pain or local hyperthermia remains
MTX doses are increased if the serum peak is too low or if the tumor does not respond enough.
60% of our patients received escalating doses

• The mean increase of dose is 40%; We had sometimes to increase the dose up to 22 G/Sqm per curse.

• With such a method we always obtain clinical response of primary OS and never more observe progression of disease during preop chemotherapy.

• With a reinforced rescue they do not suffer of increased toxicity
Response of OS after short preop HDMTX

- 4 to 5 weeks of individualized curses of HDMTX are enough even in case of fracture
Lenght of preoperative chemotherapy?

I seems safer to resect the primary as soon as the optimal dose of MTX has been evaluated by the preoperative chemotherapy.

With MTX four to five curses in 4 to 5 weeks are enough.

For that reason we always operate early after 4 to 5 weeks of MTX.
Preoperative chemotherapy can be dangerous

Too long preoperative chemotherapy may be dangerous if chemotherapy is not effective enough and may increase the risk of induction of chemoresistance and of metastases.

All these patients died
Postoperative chemotherapy

- uses HDMTX (12 additional curses at the effective dose), IFO (3 curses with 12 G/Sqm), Tep Rubicin and CDDP (3 curse).
- We use the same drugs in good and bad responders.
- Bad responders received only one curse more.
OS DD PROTOCOL
POST-OPERATIVE CHIMIO THERAPY

6 7 8

11 12 13

21 22 23

26 28

31 weeks

H D M T X

B C D

IPA

Strategy of treatment of osteosarcoma

XII national congress of tchek orthopaedics May 18 2008 Praha
Our Résults 1982-2007

1/1986 …: Individualized HDMTX

1985 HDMTX without PK

1982-1984 : Eur Adr-Cddp

Strategy of treatment of osteosarcoma  XII national congress of tchek orthopaedics May 18 2008 Praha
Conclusions

– We are all unique, all different.

– Osteosarcoma are all unique, all different.

– We all know that tailored suit fit us better than standardized suit.

– We treat severe infection with individualized antibiotherapy accorded to pharmacokinetics and antibiogram.

– We should treat patients with individualised doses of HDMTX defined during the preoperative chemotherapy by examining the response of the primary